Grass City 20% OFF

CORAL GABLES, FL / ACCESSWIRE / January 25, 2019 / The healthcare stock market has become increasingly more exciting over the last few months, with headlines detailing inventive treatments and strategic acquisitions popping up left and right. Companies in the healthcare industry have recognized that, as medical experts discover more diseases and ailments, this creates an opportunity to invest in products/services to improve the quality of life for patients. Premier Health Group (OTC:PHGRF) (CNSX:PHGI.CN) , vTv Therapeutics Inc (NASDAQ:VTVT), Canopy Growth Corp (NYSE:CGC) (TSX:WEED.TO), and Rewalk Robotics Ltd (NASDAQ:RWLK) represent four healthcare companies determined to invest in the betterment of healthcare.

Premier Health Group (OTC:PHGRF) (CNSX:PHGI.CN) is a company focused on developing nuanced approaches that combine human skill-based expertise with up and coming technologies for the healthcare industry to create optimal care solutions for their patients. Over the course of the last few months, the Company has seen impressive gains as a result of their ongoing efforts to invest in the well-being of their patients.

Premier Health Group (OTC:PHGRF) (CNSX:PHGI.CN) today announced two key new hires to support its anticipated growth in 2019 and beyond.

Following the Company’s announcement , Dr. Essam Hamza, CEO of Premier Health Group (OTC:PHGRF) (CNSX:PHGI.CN) said, “As we further our expansion, we are thrilled to officially bring on two new members to the Premier leadership team. Mr. Mena Beshay has accepted the role of CFO with the company, and Ms. Kanchan Thindal will take on the position of COO. These two highly educated individuals bring extensive financial, operations and strategic experience to Premier that will be a major asset as we enter our next phase of growth and further our patient centric mission.”

For More Information On Premier Health Group, Click Here

vTv Therapeutics Inc (VTVT) announced earlier this month that a recently released publication of a paper in Science Translational Medicine showcased one of the Company’s diabetes treatments still in the works. The paper reviewed the scientific rationale underpinning the development of TTP399 and its progression from preclinical to clinical development concluding with the positive results of the AGATA study, a phase 2 study of TTP399 in patients with type 2 diabetes.

In a press release regarding the announcement, Steve Holcombe, president, and CEO of vTv Therapeutics, said, “we are very pleased with the positive results of the AGATA study. Building on the success seen in type 2 diabetes, we are also currently conducting an adaptive phase 2 study in collaboration with the JDRF in subjects with type 1 diabetes and expect to release results from part 1 of the study later this year. This paper is a testament to the excellent pre-clinical and clinical capabilities of our researchers who were able to translate their deep understanding of GK biology into a promising clinical drug candidate.”

For More Information On vTv Therapeutics Inc, Click Here

Canopy Growth Corp (CGC) (WEED) announced earlier this month, in an effort to further extend the global reach of utilizing cannabis as a means of innovating new forms of effective medical treatment, updates regarding key European progress in the UK and Poland where its medically-focused business Spectrum Cannabis continues to build a sophisticated, pan-European cannabis production and distribution network serving the needs of physicians and their patients throughout the continent.

Following the announcement, Dr. Mark Ware, Chief Medical Officer of Canopy Growth, said, “There is significant real-world and clinical evidence supporting the safety and effectiveness of cannabis-based medicinal products. However, due to the current regulations and lack of education about medicinal cannabis among clinicians in the UK, there remain considerable obstacles to patient access. Spectrum UK has the expertise and ambition to simplify the UK medicinal cannabis landscape and ensure access to cannabis-based medicinal products for patients with great clinical unmet need.”

For More Information on Canopy Growth Corp, Click Here

ReWalk Robotics, Ltd (RWLK) announced in early November 2018 that the Company had placed its 500th robotic exoskeleton medical device. At the time of the announcement, the company said that the majority of these devices are personal systems used by individuals with spinal cord injury in their homes and communities, while others are located in rehabilitation centers to evaluate and train potential new device owners.

In a press release regarding the announcement, ReWalk CEO Larry Jasinski, said, “500 units placed is a wonderful milestone for the Company, and an important moment in our mission to improve the quality of life for individuals with lower limb disability. Most of all, we see this moment as a chance to reflect on the myriad lives that have been impacted by the technology. Every single patient was told he or she would never walk again.”

For More Information On ReWalk Robotics Ltd, Click Here

What Is Stock Price (

Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for. was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.

At Stock Price (, you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

JSG Communications, LLC, which owns , may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns , may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 (CASH) for & were paid “500,000” shares of restricted common shares (as of 1/25/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the “500,000” shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information Please click here for full disclaimer .

Contact Information:


Stock Symbols